Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 8, 2013, Pages 1036-1042

  Sanchez Padilla, Elizabeth ^a   Ardizzoni, E ^b   Sauvageot, D ^a   Ahoua, L ^a   Martin, A ^b   Varaine, F ^c   Adatu Engwau, F ^d   Akeche, G ^e   Salaniponi, F ^f   Bonnet, M ^a  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

^c MSF   (France)

^d Ugandan National Tuberculosis and Leprosy Programme   (Uganda)

^e National Leprosy Tuberculosis Program   (Kenya)

^f National Tuberculosis Control Programme Malawi   (Malawi)

Author keywords

Isoniazid; Resistance; Survey; Tuberculosis

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; DISEASE SURVEILLANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALAWI; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; UGANDA;

EID: 84880444941     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB). 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
3. Zignol M, van Gemert W, Falzon D, et al. Surveillance of antituberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
4. Bretzel G, Aziz M, Wendl-Richter U, et al. Anti-tuberculosis drug resistance surveillance in Uganda 1996-1997. Int J Tuberc Lung Dis 1999; 3: 810-815. (Pubitemid 29425952)
5. Githui W A, Juma E S, van Gorkom J, Kibuga D, Odhiambo J, Drobniewski F. Anti-tuberculosis drug resistance surveillance in Kenya, 1995. Int J Tuberc Lung Dis 1998; 2: 499-505. (Pubitemid 28326315)
6. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2009.422. Geneva, Switzerland: WHO, 2003.
7. The National AIDS Control Council and the National AIDS and STD Control Programme. National HIV prevalence in Kenya. Nairobi, Kenya: National AIDS Control Council and the National AIDS and STD Control Programme, 2007.
8. Médecins Sans Frontières, Ministry of Health and Population Chiradzulu District, Malawi. Antiretroviral therapy in primary health care: experience of the Chiradzulu programme in Malawi: case study. Geneva, Switzerland: WHO, 2004. http://www.who. int/hiv/pub/prev-care/en/chiradzulu.pdf Accessed May 2013.
9. Ministry of Health Uganda, Measure Demographic & Health Survey. Uganda HIV/AIDS Sero-behavioural Survey 2004-2005. Calverton, MD, USA: Ministry of Health and Measure DHS, 2006.
10. United Nations. Recommendations on the transport of dangerous goods. Model regulations. 15th ed. ST/SG/AC.10/1/ Rev.15. New York, NY, USA: UN, 2007.
11. Lukoye D, Cobelens F G, Ezati N, et al. Rates of anti- tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS ONE 2011; 6: e16130.
12. Warndorff D K, Yates M, Ngwira B, et al. Trends in anti- tuberculosis drug resistance in Karonga District, Malawi, 1986-1998. Int J Tuberc Lung Dis 2000; 4: 752-757. (Pubitemid 30650033)
13. Chonde T M, Basra D, Mfinanga S G M, et al. National anti- tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis 2010; 14: 967-972.
14. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drugresistant tuberculosis by 2015. WHO progress report 2011. Geneva, Switzerland: WHO, 2011.
15. Sanchez-Padilla E, Dlamini T, Ascorra A, et al. High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010. Emerg Infect Dis 2012; 18: 29-37.
16. Andrews J R, Shah N S, Weissman D, Moll A P, Friedland G, Gandhi N R. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS ONE 2010; 5: e15735.
17. Suchindran S, Brouwer E S, Van Rie A. Is HIV infection a risk factor for multi-drug-resistant tuberculosis? A systematic review. PLoS ONE 2009; 4: e5561.
18. World Health Organization. Policy statement. Automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland: WHO, 2011.
19. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2011.6. Geneva, Switzerland: WHO, 2011.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
21. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012; 16: 812-816.
22. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.